Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine.
- Authors
- Clarke, Toni-Kim; Crist, Richard C; Kampman, Kyle M; Dackis, Charles A; Pettinati, Helen M; O'Brien, Charles P; Oslin, David W; Ferraro, Thomas N; Lohoff, Falk W; Berrettini, Wade H
- Year
- 2013
- Journal
- Neuroscience letters
- PMID
- 23454283
- DOI
- 10.1016/j.neulet.2013.02.018
- PMCID
- PMC3640707
The μ-opioid receptor (MOR) binds exogenous and endogenous opioids and is known to mediate the rewarding effects of drugs of abuse. Numerous genetic studies have sought to identify common genetic variation in the gene encoding MOR (OPRM1) that affects risk for drug addiction. The purpose of this study was to examine the contribution of rare coding variants in OPRM1 to the risk for addiction. Rare and low frequency variants were selected using the National Heart Lung and Blood Institute - Exome Sequencing Project (NHLBI-ESP) database, which has screened the exomes of over 6500 individuals. Two SNPs (rs62638690 and rs17174794) were selected for genotyping in 1377 European American individuals addicted to heroin and/or cocaine. Two different SNPs (rs1799971 and rs17174801) were genotyped in 1238 African American individuals addicted to heroin and/or cocaine. Using the minor allele frequencies from the NHLBI-ESP dataset as a comparison group, case-control association analyses were performed. Results revealed an association between rs62638690 and cocaine and heroin addiction in European Americans (p=0.02; 95% C.I. 0.47 [0.24-0.92]). This study suggests a potential role for rare OPRM1 variants in addiction disorders and highlights an area worthy of future study.
No figures extracted from this document.
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Genetic and Epigenetic Approaches to Opioid Use Disorder. | Ranadeva ND et al. | — | 2025 | → |
| Genomic factors associated with substance use disorder relapse: A critical review. | Al-Marzooqi N et al. | — | 2024 | → |
| Investigating cocaine- and abstinence-induced effects on astrocyte gene expression in the nucleus accumbens | Franklin JP et al. | — | 2024 | — |
| OPRM1 Gene Polymorphism in Women with Alcohol Use Disorder. | Boroń A et al. | — | 2024 | → |
| Evaluating the role of rare genetic variation in sleep duration. | Meng P et al. | — | 2022 | → |
| Frequency of the Dopamine Receptor D3 (rs6280) vs. Opioid Receptor µ1 (rs1799971) Polymorphic Risk Alleles in Patients with Opioid Use Disorder: A Preponderance of Dopaminergic Mechanisms? | Gondré-Lewis MC et al. | — | 2022 | → |
| Molecular genetics of cocaine use disorders in humans. | Fernàndez-Castillo N et al. | — | 2022 | → |
| Pharmacogenetics of Addiction Therapy. | Graham DP et al. | — | 2022 | → |
| Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. | Davis KD et al. | — | 2020 | → |
| Haplotype-Based Association and In Silico Studies of OPRM1 Gene Variants with Susceptibility to Opioid Dependence Among Addicted Iranians Undergoing Methadone Treatment. | Tolami HF et al. | — | 2020 | → |
| Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine. | Abijo T et al. | — | 2020 | → |
| Systematic analysis of genetic variants in cancer-testis genes identified two novel lung cancer susceptibility loci in Chinese population. | Li Z et al. | — | 2020 | → |
| Impact of genetic polymorphisms on opioid misuse: a scoping review. | Ahmed S et al. | — | 2019 | → |
| Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. | Burns JA et al. | — | 2019 | → |
| Risk Factors and Prevention Strategies for Postoperative Opioid Abuse. | Zhao S et al. | — | 2019 | → |
| Elevated levels of DNA methylation at the OPRM1 promoter region in men with opioid use disorder. | Ebrahimi G et al. | — | 2018 | → |
| Molecular Genetics and New Medication Strategies for Opioid Addiction. | Hurd YL et al. | — | 2018 | → |
| The frequency of <i>DRD2</i> rs1076560 and <i>OPRM1</i> rs1799971 in substance use disorder patients from the United Arab Emirates. | Alblooshi H et al. | — | 2018 | → |
| Emergent biomarker derived from next-generation sequencing to identify pain patients requiring uncommonly high opioid doses. | Kringel D et al. | — | 2017 | → |
| Individual differences in the neuropsychopathology of addiction. | George O et al. | — | 2017 | → |
| Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. | Schwantes-An TH et al. | — | 2016 | → |
| Next-generation sequencing of human opioid receptor genes based on a custom AmpliSeq™ library and ion torrent personal genome machine. | Kringel D et al. | — | 2016 | → |
| Genetic Similarities between Compulsive Overeating and Addiction Phenotypes: A Case for "Food Addiction"? | Carlier N et al. | — | 2015 | → |
| The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review. | Bauer IE et al. | — | 2015 | → |
| Endogenous opiates and behavior: 2013. | Bodnar RJ | — | 2014 | → |
| Genetics of opiate addiction. | Reed B et al. | — | 2014 | → |